The reusable wearable and clinical intelligence system provide scalable exception management and automate vital sign collection to enhance patient monitoring.
RT’s Three Key Takeaways:
- FDA Clearance for Scalable Monitoring: The FDA-cleared BioButton Multi-Patient wearable and BioDashboard system enable continuous, automated vital sign monitoring across various care settings, including hospital units and at-home care.
- Enhanced Clinical Efficiency: The system’s rechargeable and reusable design, combined with data-driven exception management, allows clinicians to monitor hundreds of patients simultaneously.
- Improved Patient Outcomes: By shifting to high-frequency continuous monitoring, the system helps detect critical changes in patient health earlier, facilitating timely interventions.
BioIntelliSense, a continuous health monitoring and clinical intelligence company, announces US Food and Drug Administration (FDA) clearance of the rechargeable BioButton Multi-Patient wearable and BioDashboard system to grow and scale hospital virtual care programs.
The BioButton Multi-Patient medical device expands the BioIntelliSense portfolio of continuous patient monitoring solutions by offering a rechargeable and reusable inpatient solution for automating vital sign collection across medical-surgical units, specialty care areas, emergency departments, and in delivering hospital-level care at home.
The BioDashboard clinical intelligence system’s data-driven exception management enables scalable, automated trending notifications that are personalized for each patient. This facilitates the ability for one clinician to monitor hundreds of BioButton patients simultaneously in a configurable dashboard view for proactive clinical decisions.
The shift from episodic to high-frequency continuous vital sign trend monitoring with the FDA-cleared BioButton Multi-Patient wearable and BioDashboard system aims to empower clinicians to detect clinically meaningful changes in physiologic trends that create opportunities for earlier intervention and improved patient outcomes.
“We are advancing a new standard of care by automating the capture of thousands of multiparameter measurements each day and for every general care patient throughout their inpatient stay, and now the BioButton Multi-Patient wearable is conveniently rechargeable with its own dedicated in-facility charging station,” says James Mault, MD, founder and CEO of BioIntelliSense, in a release. “The introduction of the rechargeable and reusable BioButton Multi-Patient wearable, combined with the BioDashboard clinical intelligence solution, provides health systems nationwide unprecedented economies of scale in making continuous care more affordable and accessible for every patient that is admitted to the hospital.”
Continuous Care Model
The BioIntelliSense inpatient monitoring solution—powered by the new BioButton Multi-Patient wearables and charging stations, BioHub Wi-Fi gateways, BioCloud data analytics, and the BioDashboard clinical intelligence system—provides a continuous care model for improved patient safety and clinical workflow efficiencies by reducing the burden of repetitive manual tasks associated with spot check vital sign measurements and documentation.
“This staff time savings results in better prioritization of care and re-allocation of resources to those patients who need more hands-on care. Workforce efficiency is further enhanced with the BioDashboard’s exception management approach to continuous patient monitoring with low notification rates (<1 per patient per day) and high clinician engagement (99.71%) through actionable clinical insights that increase response time, reduce alert fatigue, and improve overall patient care,” according to a release from BioIntelliSense.
The BioIntelliSense BioButton and BioDashboard System is a cloud-based platform that extends from in-hospital to home and is an interoperable solution with third-party and EMR system integration and data exchange capabilities.
Photo caption: The FDA-cleared BioIntelliSense BioButton Multi-Patient wearable and BioDashboard System for continuous patient monitoring.
Photo credit: Business Wire
